research support from: RB has received grants or research support from AbbVie, Merck, and Roche; and has received consultation fees or honoraria for serving as a speaker for AbbVie, Bristol-Myers Squibb, Janssen, Lilly, Merck, Pfizer, and Roche., Jacob Aelon Grant/research support from: JA has received grants or research support from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Galapagos/Gilead, Genentech, GlaxoSmithKline, Lilly, Mallinckrodt, Nektar Therapeutics, Nichi-Iko, Novartis, Pfizer, Regeneron, Roche, Sanofi, Selecta Biosciences, and UCB., Gabriela Alperovich Shareholder of: GA is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Employee of: GA is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Ying Zhang Shareholder of: YZ is a former AbbVie employee, and may hold AbbVie stock or stock options., Employee of: YZ is a former AbbVie employee, and may hold AbbVie stock or stock options., Zailong Wang Shareholder of: ZW is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Employee of: ZW is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Ahmed M. Soliman Shareholder of: AS is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Employee of: AS is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Ann Eldred Shareholder of: AE is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Employee of: AE is a full-time employee of AbbVie, and may hold AbbVie stock or stock options., Alan Kivitz Shareholder of: AK is a shareholder of or has received honoraria or fees as a consultant, speaker, or expert witness for AbbVie, Boehringer Ingelheim, Celgene, Flexion, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB., Speakers bureau: AK is a shareholder of or has received honoraria or fees as a consultant, speaker, or expert witness for AbbVie, Boehringer Ingelheim, Celgene, Flexion, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB., Consultant of: AK is a shareholder of or has received honoraria or fees as a consultant, speaker, or expert witness for AbbVie, Boehringer Ingelheim, Celgene, Flexion, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB.

DOI: 10.1136/annrheumdis-2021-eular.2695

OP0229

THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021

L. C. Coates¹, E. Soriano², N. Corp³, H. Bertheussen⁴, K. Callis-Duffin⁵, C. Barbosa Campanholo⁶, J. Chau⁷, L. Eder⁸, D. Fernandez⁹, O. Fitzgerald¹⁰, A. Garg¹¹, D. D. Gladman¹², N. Goel^{13,14}, S. Grieb¹⁵, P. Helliwell¹⁶, M. E. Husni¹⁷, D. Jadon¹⁸, A. Katz¹⁹, D. Laheru²⁰, J. Latella²¹, Y. Y. Leung²², C. Lindsay²³, E. Lubrano²⁴, L. Mazzuocollo²⁵, R. McDonald²⁶, P. J. Mease^{27,28}, D. O'Sullivan²⁹, A. Ogdie³⁰, W. Olsder³¹, L. Schick¹⁵, I. Steinkoenig³², M. De Wit³³, D. Van der Windt³⁴, A. Kavanaugh³⁵. ¹University of Oxford, NDORMS, Oxford, United Kingdom; ²Hospital Italiano de Buenos Aires, Rheumatology, Buenos Aires, Argentina; ³Keele University, School of Primary, Community and Social Care, Keele, United Kingdom; ⁴GRAPPA, Patient Research Partner, Oslo, Norway; ⁵University of Utah, Dermatology, Salt Lake City, United States of America; ⁶Santa Casa de Sao Paulo, Rheumatology, Sao Paulo, Brazil; ⁷GRAPPA, Patient Research Partner, Hong Kong, Hong Kong (SAR); ⁸University of Toronto, Rheumatology, Toronto, Canada; ⁹Hospital Universitario San Ignacio, Rheumatology, Bogota, Colombia; ¹⁰University College Dublin, Rheumatology, Dublin, Ireland; ¹¹Donald and Barbara Zucker School of Medicine at Hofstra Northwell, Dermatology, Hempstead, United States of America; ¹²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada; ¹³GRAPPA, Patient Research Partner, Durham, United States of America; ¹⁴Duke University, Rheumatology, Durham, United States of America; ¹⁵GRAPPA, Patient Research Partner, Seattle, United States of America; ¹⁶University of Leeds, Leeds Institute of Rheumatology and Musculoskeletal Medicine, Leeds, United Kingdom; ¹⁷Cleveland Clinic Main Campus, Rheumatology, Cleveland, United States of America; ¹⁸University of Cambridge, Rheumatology, Cambridge, United Kingdom; ¹⁹GRAPPA, Patient Research Partner, Haifa, Israel; ²⁰Churchill Hospital, Dermatology, Oxford, United Kingdom; ²¹GRAPPA, Patient Research Partner, Connecticut, United States of America; ²²Singapore General Hospital, Rheumatology, Singapore, Singapore; ²³GRAPPA, Patient Research Partner, Propser, United States of America; ²⁴University of Molise, Rheumatology, Campobasso, Italy; ²⁵Hospital Italiano de Buenos Aires, Dermatology, Buenos Aires, Argentina; ²⁶GRAPPA, Patient Research Partner, Toronto, Canada; ²⁷Swedish Medical Center, Rheumatology, Seattle, United States of America; ²⁸University of Washington, Rheumatology, Seattle, United States of America; ²⁹GRAPPA, Patient Research Partner, Dublin, Ireland; ³⁰University of Pennsylvania, Rheumatology, Philadelphia, United States of America; ³¹GRAPPA, Patient Research Partner, Eindhoven, Netherlands; ³²GRAPPA, Patient Research Partner, Cleveland, United States of America; ³³GRAPPA, Patient Research Partner, Amsterdam, Netherlands; ³⁴Keele University, School of Primary Community and Social Care, Keele, United Kingdom; ³⁵University of California San Diego, Rheumatology, La Jolla, United States of America

Background: Since the 2015 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably.

Objectives: The goal of the GRAPPA recommendations update is to develop high quality, evidence-based recommendations for the treatment of PsA, including related conditions and comorbidities.

Methods: GRAPPA rheumatologists, dermatologists and patient research partners (PRPs) updated overarching principles for the management of adults with PsA by consensus. Principles considering use of biosimilars and tapering/discontinuing of therapy were added to this update. Systematic literature searches based on data publicly available from three databases (MEDLINE, EMBASE, and Cochrane CENTRAL) were conducted from the end of the previous recommendations' searches through August 2020. Additional abstract searches were performed for conference presentations in 2017-2020. Searches covered PsA treatments (peripheral arthritis, axial arthritis, enthesitis, dactylitis, skin, and nail disease). Additional searches were performed for related conditions (uveitis and IBD) and comorbidities evaluating their impact on safety and treatment outcomes. Individual groups assessed the risk of bias and applied the GRADE system to generate strong or conditional recommendations for therapies within the domain groups and for the management of comorbidities and related conditions. These recommendations were then incorporated into an overall treatment schema.

Results: Updated, evidence-based treatment recommendations are shown (Table 1). Since 2015, many new medications have been incorporated. Additional results for older medications, such as methotrexate, have been published across PsA domains. Based on the evidence, the treatment recommendations developed by individual groups were incorporated into the overall schema including principles for management of arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease in PsA, and associated conditions (Figure 1). Choice of therapy for an individual should ideally address all of the domains that impact on that patient, supporting shared decision making with the patient involved. Additional consideration in the recommendations was given to key associated conditions and comorbidities as these often impact on therapy choice.

Conclusion: These GRAPPA treatment recommendations provide up to date, evidence-based guidance to providers who manage and treat adult patients with PsA. These recommendations are based on domain-based strategy for PsA and supplemented by overarching principles developed by consensus of GRAPPA members.

Indication	Strong For	Conditional For	Conditional Against	Strong Against	Insufficient evidence
Peripheral Arthritis	csDMARDs, TNFi, PDE4i, IL-12/23i, IL-17i, IL-23i, JAKi	NSAIDs, oral CS, IA CS,	IL-6i,		
DMARD Naive					
Peripheral Arthritis	TNFi, IL-12/23i, IL-17i, IL-23i, JAKi	PDE4i, other csDMARD, NSAIDs, oral CS, IA CS,	IL-6i,		
DMARD IR		NSAIDs, oral CS, IA CS,			
Peripheral Arthritis	TNFi, IL-17i, IL-23i, JAKi,	CS, IA CS, IL-12/23i, PDE4i, CTLA-4-Ig	IL-6i,		
bDMARD IR		CS SIJ injections, bisphosphonates		cs DMARDs, IL-6i,	IL-12/23i, IL-23i
Axial arthritis, Biologic Naive	NSAIDs, Physiotherapy, simple analgesia, TNFi, IL-17i, JAKi				
Axial PsA, Biologic IR	NSAIDs, Physiotherapy, simple analgesia, TNFi, IL-17i, JAKi			csDMARDs, IL-6i,	IL-12/23i, IL-23i
Enthesitis	TNFi, IL-12/23i, IL-17i, PDE4i, IL-23i, JAKi	NSAIDs, physiotherapy, CS injections, MTX injections, MTX		IL-6i,	Other cs DMARDs
Dactylitis	TNFi IL-12/23i, IL-17i, IL-23i, JAKi, PDE4i	NSAIDs, CS injections, MTX	Other csDMARDs		
Psoriasis	Topicals, phototherapy, csDMARDs, TNFi, IL-12/23i, IL-17i, IL-23i, PDE4i, JAKi	Acitretin			
Nail psoriasis	TNFi, IL-12/23i, IL-17i, IL-23i, PDE4i	Topical CS, tacrolimus and calcipotriol combination or individual therapies, Pulsed dye laser, csDMARDs, acitretin, JAKi			Topical Cyclosporine / Tazarotene, Fumarate, Fumaric Acid Esters, UVA and UVB Phototherapy, Alitretinoin
IBD	TNFi (not ETN), IL-12/23i, JAKi			IL-17i	
Uveitis	TNFi (not ETN)

Disclosure of Interests: Laura C Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Pfizer, and Novartis, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Grant/research support from: AbbVie, Janssen, Novartis Pharma, Pfizer, Roche, and UCB, Nadia Corp: None declared, Heidi Bertheussen Consultant of: Pfizer, Kristina Callis-Duffin Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Lilly, Janssen, Novartis, Pfizer, Sienna Biopharmaceuticals, Stiefel Laboratories, UCB, Ortho Dermatologics, Inc, Regeneron Pharmaceuticals, Inc., Anaptys Bio, Boehringer Ingelheim., Cristiano Barbosa Campanholo Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Jeffrey Chau: None declared, Lihi Eder Consultant of: Abbvie, UCB, Janssen, Eli Lilly, Pfizer, Novartis, Grant/research support from: Abbvie, UCB, Janssen, Eli Lilly, Pfizer, Novartis, Daniel Fernandez Consultant of: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Bristol, Grant/research support from: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Bristol, Oliver Fitzgerald Speakers bureau: AbbVie, Janssen and Pfizer Inc, Consultant of: BMS, Celgene, Eli Lilly, Janssen and Pfizer Inc, Grant/research support from: AbbVie, BMS, Eli Lilly, Novartis and Pfizer Inc, Amit Garg Consultant of: Abbvie, Amgen, Asana Biosciences, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, InflaRx, Janssen, Pfizer, UCB, Viela Biosciences, Grant/research support from: Abbvie, Dafna D Gladman Consultant of: Abbvie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Jansen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, Eli Lilly, Jansen, Novartis, Pfizer and UCB, Niti Goel: None declared, Suzanne Grieb: None declared, Philip Helliwell Speakers bureau: Janssen, Novartis, Pfizer, Consultant of: Eli Lilly, M Elaine Husni Consultant of: Abbvie, Amgen, Janssen, Novartis, Lilly, UCB, Regeneron, and Pfizer, Deepak Jadon Speakers bureau: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Arnon Katz: None declared, Dhruvkumar Laheru: None declared, John Latella: None declared, Ying Ying Leung Speakers bureau: Novartis, AbbVie, Eli Lilly, Janssen, Consultant of: Pfizer and Boehringer Ingelheim, Grant/research support from: Pfizer and conference support from AbbVie, Christine Lindsay Shareholder of: Amgen, Employee of: Aurinia pharmaceuticals, Ennio Lubrano Speakers bureau: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Consultant of: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Luis Mazzucolo Speakers bureau: Abbvie, Amgen, Novartis, Eli Lilly, Jansen, Consultant of: Abbvie, Amgen, Novartis, Eli Lilly, Jansen, Roland McDonald: None declared, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer, SUN and UCB, Denis O'Sullivan: None declared, Alexis Oggie Consultant of: AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, and Pfizer, Grant/research support from: Novartis and Pfizer and Amgen, Wendy Olser: None declared, Lori Schick: None declared, Ingrid Steinkoenig: None declared, Maarten de Wit Consultant of: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche, Danielle van der Windt: None declared, Arthur Kavanaugh Speakers bureau: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB

DOI: 10.1136/annrheumdis-2021-eular.4091

OP0230

EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

L. C. Coates¹, L. Gossec², E. Theander³, P. Bergmans⁴, M. Neuhold⁵, C. Karykær⁶, M. Shawi⁷, W. Noelf⁸, G. Schett¹, I. McInnes⁸. ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; ²Sorbonne Université, Professor of Rheumatology, Paris, France; ³Janssen Scientific Affairs, LLC, Immunology, Solna, Sweden; ⁴Janssen, Biostatistics, Breda, Netherlands; ⁵Janssen Scientific Affairs, LLC, Immunology, Brussels, Belgium; ⁶Janssen Global Services, LLC, Immunology, Horsham, United States of America; ⁷University of Erlangen-Nuremberg, Internal Medicine 3, Erlangen, Germany; ⁸University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, United Kingdom

Background: Guselkumab (GUS), a selective monoclonal antibody targeting the interleukin-23p19 subunit, has demonstrated efficacy in 2 pivotal Ph3 psoriatic arthritis (PsA) studies (DISCOVER-1, DISCOVER-2).

Objectives: Evaluate GUS efficacy and safety in PsA patients (pts) with inadequate response (IR) to tumor-necrosis-factor inhibition (TNFi) through Week24 (W24) of the Ph3b COSMOS study.

Methods: In this randomized, double-blind, placebo (PBO)-controlled trial, 285 pts with active PsA (≥ 3 swollen & ≥ 3 tender joints) who demonstrated lack of benefit or intolerance to 1-2 TNFi were randomized 2:1 to subcutaneous GUS 100mg (n=189) or PBO (n=96) at W0, W4, then every 8 weeks (Q8W) through W44 (with PBO crossover to GUS at W24). At W16, pts who met early escape (EE) criteria ($<5\%$ improvement in both tender & swollen joint counts) also could switch from PBO to GUS. The primary efficacy endpoint was ACR20 response at W24 among randomized, treated pts. Pts missing ACR20 data at W24 or who met treatment failure criteria (including meeting EE criteria at W16) were considered nonresponders (NRs). Subgroup analyses were performed to assess consistency of primary treatment effect based on demographics, disease characteristics, and medication use at baseline. Prespecified sensitivity analyses included 'Per-Protocol' (PP) (excluded pts with major protocol deviations) and 'EE-Correction' (included pts incorrectly routed to EE) analyses. Adverse events (AEs) were summarized by treatment received.

Results: Baseline characteristics were similar across GUS and PBO pts, though a higher proportion of females and more severe joint symptoms were seen in the GUS group. At W24, 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 ($p<0.001$) (Figure). GUS was superior to PBO for all major secondary endpoints. Efficacy was consistent across subgroups defined by baseline characteristics, including in pts who discontinued prior TNFi use due to inadequate efficacy (84% GUS vs 81% PBO) and safety (16% GUS vs 19% PBO) (Table). 20 pts (12 GUS, 8 PBO) were incorrectly routed to EE. Results of PP (48.8% vs 23.8%) and EE-correction (48.1% vs 19.8%) sensitivity analyses were consistent with the primary analysis (Figure). AEs were similar between GUS- and PBO-treated pts (Table).

Table 1. Baseline characteristics of, and adverse events reported by, randomized and treated COSMOS pts

	GUS 100 mg Q8W (N=189)	PBO (N=96)
Age, y	49	49
Sex, Female	54%	46%
Duration of PsA, y	8.3	8.7
Body mass index, kg/m ²	29	31 ^a
Swollen (0-66) / tender (0-68) joint count	10 / 21	9 / 18
Pt pain / Pt global arthritis / Physician global disease, 0-10 cm VAS	6.5 / 6.5 / 6.9	6.0 / 6.2 / 6.4
Health Assessment Questionnaire-Disability Index, 0-3	1.3 ^b	1.2
C-reactive protein, mg/dL	1.2 ^b	1.2
Methotrexate use at baseline	56%	53%
Psoriatic body surface area, %	17.9	13.4
Number of prior TNFi: 1 / 2	88% / 12%	89% / 11%
Reason for prior TNFi discontinuation: Efficacy / Safety	84% / 16%*	81% / 19%*
Pts with ≥ 1 AE / SAE	37% / 3%	48% / 3%
Pts with ≥ 1 infection / serious infection	18% / 0%	20% / 0%
Pts with ≥ 1 AE leading to study agent discontinuation	2%	2%
Pts with ≥ 1 malignancy	0.4%	0
Pts with ≥ 1 injection-site reaction	2%	1%

Data shown are mean or %. ^aN=95; ^bN=188. *Missing for 1 pt. SAE = serious adverse events; VAS = visual analog scale

Conclusion: In this Ph3b, placebo-controlled study of PsA pts with IR to 1-2 TNFi, GUS 100mg Q8W elicited a significantly higher ACR20 response rate vs.